Analyst Research

Report Title Price
Thomson Reuters Stock Report - ZHEJIANG MEDICINE CO., LTD. (600216-SH)
Provider: Thomson Reuters Stock Report
$25.00
Buy
Zhejiang Medicine Co Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
$20.00
Buy
Wright Investors Service Comprehensive Report for Zhejiang Medicine Co., Ltd.
Provider: Wright Reports
$472.00
Buy
Zhejiang Medicine Co., Ltd. (600216) - Financial and Strategic SWOT Analysis Review
Provider: GlobalData
$125.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Zhejiang Medicine Co., Ltd. Announces Private Placement Plan


Friday, 10 Feb 2012 07:00pm EST 

Zhejiang Medicine Co., Ltd. announced that it will issue up to 70 million A shares of common stock with par value of RMB 1 per share at not less than RMB 18.73 per share, to raise up to RMB 1.6 billion to invest in a production base construction project. 

Latest Developments for Zhejiang Medicine Co Ltd

Latest Key Developments in Pharmaceuticals

Company Quote

Zhejiang Medicine Co Ltd
(600216.SS)
21.38
0.08 +0.38%
17 May 2013